

AS CONCED.

USSN - 09/987,107

construct, comprising an amino acid sequence having at least 70% sequence identity to one of the sequences SEQ ID NO 3 to SEQ ID NO 11, or SEQ ID NO 14.

37 (amended). The composition of claim 1, further comprising pharmaceutical acceptable excipients, adjuvants, or additives.

A6
39 (amended). The construct of claim 38, further comprising a spacer peptide between the apo-A component and X, wherein the spacer peptide comprises at least two amino acids.

A7
43 (amended). The construct according to claim 38, wherein component X comprises at least one amphipathic helix containing apolipoprotein.

A8
50 (amended). The construct of claim 38, wherein the oligomerising module is of non-peptide nature.

A9
53 (amended). The construct of claim 52, wherein the stable complex comprises a coiled coil structure.

A10
58 (amended). The construct of claim 57, wherein the cysteine residue no. 50 is substituted by a serine residue, a threonine residue, or a methionine residue.

A11
62 (amended). The construct according to claim 38, comprising an amino acid sequence having at least 70% sequence identity to at least one of the sequences SEQ ID NO 3 to SEQ ID NO 11, or SEQ ID NO 14.

A12
64 (amended). Nucleic acid according to claim 63, encoding an amino acid sequence having at least 70% amino acid sequence identity to any of SEQ ID NO 2 to SEQ ID NO 11 or SEQ ID NO 14.

A13
68 (amended). A method for the production of an apolipoprotein construct as defined in claim 1, comprising the steps of:

- culturing a transformed host cell under conditions promoting the expression of a protein construct according to claim 1, and
- obtaining and recovering said protein construct.

A14
70 (amended). The method of claim 69, wherein the pharmaceutical composition is administered intravenously, intraarterially, intramuscularly, transdermally, pulmonary,